Aktienanalyse zu CVRx Inc (CVRX)

KI-Analyse of CVRx Inc (CVRX)

Verkaufen

CVRx Inc is not a good buy right now due to significant financial and operational challenges. The current price is $0.8672, which is down 87.79% year-to-date. The company has a very low RSI of 19.218, indicating it is oversold, but this is coupled with a concerning forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the latest analyst ratings have downgraded the price targets significantly, with Craig-Hallum lowering it to $1.25 from $4, reflecting ongoing headwinds in sales execution and reimbursement challenges. The main risk is the high debt-to-equity ratio of 293.54%, indicating potential financial instability.

Bewertungskennzahlen

Das aktuelle erwartete KGV von CVRx Inc (CVRX) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -5.62.

Erwartetes KGV

Stark überbewertet

5J-Durchschnitt P/E

-5.62

Aktuelles P/E

0.00

Überbewertet

-3.36

Unterbewertet

-7.88

Erwartetes EV/EBITDA

Überbewertet

5J-Durchschnitt EV/EBITDA

-3.88

Aktuelles EV/EBITDA

-0.63

Überbewertet

-1.19

Unterbewertet

-6.56

Erwartetes KUV

Unterbewertet

5J-Durchschnitt P/S

5.40

Aktuelles P/S

0.59

Überbewertet

8.50

Unterbewertet

2.30

Alphio-AI-Kursszenarien für CVRX

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%CVRX

$11.10

Szenariopreis

B

Basis

Basis · 50%CVRX

$9.61

Szenariopreis

B

Bärisch

Bärisch · 25%CVRX

$8.24

Szenariopreis

Whales, die CVRX halten

N

New Enterprise Associates, Inc.

+ HältCVRX

+0.00%

3-Monats-Rendite

CVRX FAQ – beantwortet von Alphio AI

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

CVRx Inc is not a good buy right now due to significant financial and operational challenges. The current price is $0.8672, which is down 87.79% year-to-date. The company has a very low RSI of 19.218, indicating it is oversold, but this is coupled with a concerning forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the latest analyst ratings have downgraded the price targets significantly, with Craig-Hallum lowering it to $1.25 from $4, reflecting ongoing headwinds in sales execution and reimbursement challenges. The main risk is the high debt-to-equity ratio of 293.54%, indicating potential financial instability.